DongKook Life Science Co., Ltd. Logo

DongKook Life Science Co., Ltd.

A pharmaceutical firm specializing in contrast media for diagnostic imaging and medical devices.

303810 | KO

Overview

Corporate Details

ISIN(s):
KR7303810006
LEI:
Country:
South Korea
Address:
서울특별시 강남구 테헤란로108길 7, 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

DongKook Life Science Co., Ltd., established in 2017, is a specialized pharmaceutical company focused on diagnostic medicine and medical devices. The company's core business involves the development, manufacturing, and sale of contrast media products used in diagnostic imaging, such as X-ray and nuclear magnetic resonance (MRI). In addition to its diagnostic pharmaceutical products, DongKook Life Science also distributes medical and diagnostic equipment. The company leverages key technologies in desalting, specialized purification, and sterilization to ensure product quality and innovation. With a global network spanning 17 countries, it aims to be a customer-centered, world-class provider dedicated to improving patient health.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-08-22 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.5 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.5 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-08-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 999.9 KB
2025-08-06 00:00
Share Issue/Capital Change
권리락 (무상증자)
Korean 3.5 KB
2025-07-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 70.2 KB
2025-07-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-07-29 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(무상증자결정)
Korean 14.2 KB

Automate Your Workflow. Get a real-time feed of all DongKook Life Science Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DongKook Life Science Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DongKook Life Science Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.